Senseonics Holdings, Inc. (SENS)
NASDAQ: SENS · Real-Time Price · USD
7.00
-0.18 (-2.51%)
Apr 29, 2026, 10:01 AM EDT - Market open
Company Description
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Senseonics Holdings, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Timothy Goodnow |
Contact Details
Address: 20451 Seneca Meadows Parkway Germantown, Maryland 20876-7005 United States | |
| Phone | 301 515 7260 |
| Website | senseonics.com |
Stock Details
| Ticker Symbol | SENS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001616543 |
| CUSIP Number | 81727U303 |
| ISIN Number | US81727U3032 |
| Employer ID | 47-1210911 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy T. Goodnow Ph.D. | President, Chief Executive Officer and Director |
| Dr. Mukul Jain Ph.D. | Chief Operating Officer |
| Dr. Francine Ratner Kaufman M.D. | Chief Medical Officer and Director |
| Brian B. Hansen | Chief Commercial Officer and Director |
| Kenneth L. Horton J.D. | General Counsel and Corporate Development Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2026 | DEFR14A | Filing |
| Apr 6, 2026 | ARS | Filing |
| Apr 6, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 6, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 10-K | Annual Report |
| Mar 2, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 8-K | Current Report |